Experimental animal tests have shown that blocking CB1 decreases appetite and may improve the evolution of neurodegenerative and psychiatric diseases (Alzheimer’s disease, schizophrenia, multiple sclerosis). The gene discussed is CNR1; the disease is early-onset autosomal dominant Alzheimer disease.